New research supported by the National Institutes of Health?s National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) shows that the anticonvulsant medication gabapentin, which is used for certain types of seizures, can be an effective treatment for the pain and other symptoms associated with the common, often hard-to-treat chronic pain disorder, fibromyalgia.
Obese men who find themselves short of breath even after moderate physical activity are invited to participate in a study by UT Southwestern Medical Center and the Institute for Exercise and Environmental Medicine.
To encourage healthy lifestyles among food stamp participants, USDA?s Food and Nutrition Service today launched ?Loving Your Family, Feeding Their Future: Nutrition Education through the Food Stamp Program,? an initiative to help low income families make healthy food choices and increase their physical activity.
Researchers have discovered the first inherited gene mutation that increases a person’s risk for chronic lymphocytic leukemia (CLL), one of the most common forms of the disease.
The G8 leaders promised an increase in investment in programs to fight AIDS, tuberculosis, and malaria, but the $60 billion total will still be only one-third of what the UN says is needed over the next five years. Together, these diseases kill about 16,000 people each day.
Refugees in Australia have relatively low rates of hospital use, but they may be experiencing barriers to accessing hospital-based health care, refugee health specialists said in the latest edition of the ‘Medical Journal of Australia’.
A research abstract that will be presented Monday at SLEEP 2007, the 21st Annual Meeting of the Associated Professional Sleep Societies (APSS) finds that the health care costs of patients with insomnia are higher than for those without insomnia.
Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) and Active Biotech AB (OMX NORDIC: ACTI) announced that the companies are initiating a clinical Phase III program for laquinimod, a novel once-daily, orally administered immunomodulatory compound for the treatment of relapsing multiple sclerosis (RMS).
GlaxoSmithKline plc announced results from an international, pivotal Phase III study of its investigational non-peptide oral platelet growth factor, Revolade? (eltrombopag). Data from this study showed that eltrombopag at 50-75mg once daily resulted in a statistically significant increase in platelet counts and also reduced bleeding in adult patients with chronic idiopathic thrombocytopenia purpura (ITP).
Self-rated health is a strong predictor of functional decline and mortality for elderly people presenting to a hospital emergency department, according to a new study published in the latest issue of Emergency Medicine Australasia, the journal of the Australasian College for Emergency Medicine.